CSIMarket
 


Harvard Bioscience Inc  (HBIO)
Other Ticker:  
 
 

HBIO's Revenue Growth by Quarter and Year

Harvard Bioscience Inc's Revenue results by quarter and year




HBIO Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter December - 28.70 28.43 33.06
III Quarter September - 24.73 26.92 29.66
II Quarter June - 28.67 29.21 29.20
I Quarter March 23.77 29.98 28.78 26.99
FY   23.77 112.08 113.34 118.91



HBIO Revenue first quarter 2024 Y/Y Growth Comment
Harvard Bioscience Inc reported decline in Revenue in the first quarter 2024 by -20.71% to $ 23.77 millions, from the same quarter in 2023.
The contraction in the first quarter 2024 Harvard Bioscience Inc's Revenue compares unfavorably to the Company's average Revenue growth of 0.89%.

Looking into first quarter 2024 results within Laboratory Analytical Instruments industry 8 other companies have achieved higher Revenue growth. While Harvard Bioscience Inc' s Revenue fall of -20.71% ranks overall at the positon no. 1362 in the first quarter 2024.




HBIO Revenue ( Y/Y Growth %) 2024
2023 2022 2021
IV Quarter December - 0.95 % -14 % 6.71 %
III Quarter September - -8.14 % -9.24 % 23.38 %
II Quarter June - -1.85 % 0.03 % 25.27 %
I Quarter March -20.71 % 4.17 % 6.63 % 13.55 %
FY   - -1.11 % -4.68 % 16.46 %

Financial Statements
Harvard Bioscience Inc's first quarter 2024 Revenue $ 23.77 millions HBIO's Income Statement
Harvard Bioscience Inc's first quarter 2023 Revenue $ 29.98 millions Quarterly HBIO's Income Statement
New: More HBIO's historic Revenue Growth >>


HBIO Revenue (Quarter on Quarter Growth %)

2024
2023 2022 2021
IV Quarter December - 16.05 % 5.61 % 11.46 %
III Quarter September - -13.74 % -7.84 % 1.58 %
II Quarter June - -4.37 % 1.49 % 8.19 %
I Quarter March -17.17 % 5.45 % -12.95 % -12.88 %
FY (Year on Year)   - -1.11 % -4.68 % 16.46 %




Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #9
Healthcare Sector #222
Overall #1362

Revenue Y/Y Growth Statistics
High Average Low
18.54 % 0.89 % -14.26 %
(Dec 31 2018)   (Sep 30 2020)
Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #9
Healthcare Sector #222
Overall #1362
Revenue Y/Y Growth Statistics
High Average Low
18.54 % 0.89 % -14.26 %
(Dec 31 2018)   (Sep 30 2020)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Harvard Bioscience Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
28.9 % 0.33 % -23.25 %
(Dec 31 2020)  


HBIO's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Harvard Bioscience Inc reported fall in Revenue sequentially by -17.17% to $ 23.77 millions, from $ 28.70 millions released in the previous reporting period.

Even seasonal influence which commonly energize I. Quarter 2024 performance, this simply could not be enough to recover HBIO's performance, Jamie  Walker, market expert based in Dallas said and continued that average sequential Revenue growth is at 0.33% for the Laboratory Analytical Instruments's company.

Within Laboratory Analytical Instruments industry 8 other companies have achieved higher Revenue quarter on quarter growth. While Harvard Bioscience Inc's Revenue growth quarter on quarter, overall rank is 2141.


Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #9
Healthcare Sector #276
Overall #2141
Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #9
Healthcare Sector #276
Overall #2141
Revenue Q/Q Growth Statistics
High Average Low
28.9 % 0.33 % -23.25 %
(Dec 31 2020)  


HBIO's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Harvard Bioscience Inc realized fall in Revenue from the previous quarter by -17.17% to $ 23.77 millions, from $ 28.70 millions declared a quarter before.

Even periodic circumstance were not able to rescue the I. Quarter for the Harvard Bioscience Inc, Jamie  Walker, market expert based in Dallas pointed out, he mentioned some pessimism conserning HBIO's outlook and continued that average sequential Revenue growth is at 0.33% for HBIO.

Within Laboratory Analytical Instruments industry 8 other companies have achieved higher Revenue quarter on quarter growth. While Harvard Bioscience Inc's Revenue growth quarter on quarter, overall rank is 2141.


Harvard Bioscience Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2024)
12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
Cumulative Revenue 12 Months Ending $ 105.87 $ 112.07 $ 111.80 $ 114.00 $ 114.53
Y / Y Revenue Growth (TTM) -7.56 % -1.12 % -5.22 % -5.56 % -5.1 %
Year on Year Revenue Growth Overall Ranking # 1772 # 1454 # 1344 # 1726 # 669
Seqeuential Revenue Change (TTM) -5.53 % 0.24 % -1.93 % -0.47 % 1.06 %
Seq. Revenue Growth (TTM) Overall Ranking # 1362 # 1419 # 2324 # 2506 # 2196




Cumulative Revenue growth Comment
Harvard Bioscience Inc's cumulative 12 months Revenue continue to decline, but on the faster rate at -7.56% year on year, at Mar 31 2024 compare to the -1.12% decrease at Dec 31 2023. If the Harvard Bioscience Inc's fiscal year would end at Mar 31 2024, annual Revenue would be $106 millions.

In the Healthcare sector 264 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1454 to 1772.

Revenue TTM Q/Q Growth Statistics
High Average Low
18.54 %
0.89 %
-14.26 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 9
Healthcare Sector # 265
Overall # 1772

Revenue TTM Y/Y Growth Statistics
High Average Low
18.54 %
0.89 %
-14.26 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 9
Sector # 222
S&P 500 # 1362
Cumulative Revenue growth Comment
Harvard Bioscience Inc's cumulative 12 months Revenue continue to decline, but on the faster rate at -7.56% year on year, at Mar 31 2024 compare to the -1.12% decrease at Dec 31 2023. If the Harvard Bioscience Inc's fiscal year would end at Mar 31 2024, annual Revenue would be $106 millions.

In the Healthcare sector 264 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1454 to 1772.

Revenue TTM Q/Q Growth Statistics
High Average Low
18.54 %
0.89 %
-14.26 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 9
Healthcare Sector # 265
Overall # 1772

Revenue TTM Y/Y Growth Statistics
High Average Low
18.54 %
0.89 %
-14.26 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 9
Sector # 222
S&P 500 # 1362




Other Revenue Growth
Laboratory Analytical Instruments Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
HBIO's Revenue Growth Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for HBIO's Competitors
Revenue Growth for Harvard Bioscience Inc's Suppliers
Revenue Growth for HBIO's Customers

You may also want to know
HBIO's Annual Growth Rates HBIO's Profitability Ratios HBIO's Asset Turnover Ratio HBIO's Dividend Growth
HBIO's Roe HBIO's Valuation Ratios HBIO's Financial Strength Ratios HBIO's Dividend Payout Ratio
HBIO's Roa HBIO's Inventory Turnover Ratio HBIO's Growth Rates HBIO's Dividend Comparisons



Companies with similar Revenue decline for the quarter ending Mar 31 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2024
Collegium Pharmaceutical inc -0.21%$ -0.215 millions
Mettler Toledo International Inc-0.30%$ -0.300 millions
3m Company-0.35%$ -0.349 millions
Icu Medical Inc-0.42%$ -0.423 millions
Lifeloc Technologies Inc -0.51%$ -0.513 millions
Regeneron Pharmaceuticals Inc -0.54%$ -0.541 millions
Envista Holdings Corporation-0.62%$ -0.622 millions
Orgenesis Inc -0.70%$ -0.704 millions
Vyne Therapeutics Inc -1.01%$ -1.010 millions
Ge Healthcare Technologies Inc -1.50%$ -1.502 millions
Baxter International Inc -1.56%$ -1.562 millions
Y mabs Therapeutics inc -1.58%$ -1.580 millions
Pacific Biosciences Of California Inc -1.59%$ -1.589 millions
Cartesian Therapeutics Inc -1.65%$ -1.650 millions
Viatris Inc -1.76%$ -1.762 millions
Ocuphire Pharma Inc -2.17%$ -2.173 millions
Vaso Corporation-2.51%$ -2.513 millions
Dentsply Sirona Inc -2.56%$ -2.556 millions
Alpha Pro Tech Ltd -2.78%$ -2.775 millions
Prestige Consumer Healthcare Inc -2.82%$ -2.817 millions
West Pharmaceutical Services Inc -2.99%$ -2.986 millions
Integra Lifesciences Holdings Corp-3.14%$ -3.144 millions
Accelerate Diagnostics Inc -3.17%$ -3.165 millions
National Research Corporation-3.18%$ -3.180 millions
Catheter Precision Inc -3.53%$ -3.529 millions
Elanco Animal Health Inc-4.14%$ -4.137 millions
Ptc Therapeutics inc -4.66%$ -4.657 millions
Foghorn Therapeutics Inc -4.88%$ -4.879 millions
Aclaris Therapeutics Inc -5.14%$ -5.142 millions
Avantor Inc -5.65%$ -5.645 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com